Authors
Latest:
OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLCIn an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.
Latest:
Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone LymphomaJuan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.
Latest:
The Important Role of Cell Therapy in Multiple Myeloma: Three Reasons Why It’s Here to StayDr. Sidana shares insights on how CAR T cell therapy is giving patients with relapsed or refractory multiple myeloma a chance at remission
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
HER2+ Advanced Breast Cancer: Selecting Third-Line TherapySara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.
Latest:
Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant CyclophosphamideThis article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Key Takeaways from the PARADIGM StudyDrs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.
Latest:
Trevor J. Pugh, PhD, on Reducing the Burden of Serial Testing for MMRd With 1 Sequencing ProtocolCancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.
Latest:
Toxicity Management in Patients With Multiple MyelomaExperts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.
Latest:
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case ReportHans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Relapsed/Refractory CLL: Key Takeaways and Ongoing ChallengesClosing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
Mezigdomide Combos Yield Encouraging Responses in R/R Multiple MyelomaMany patients with relapsed/refractory multiple myeloma appear to remain on treatment with mezigdomide-based regimens for more than 1 year, according to Albert Oriol, PhD.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
Latest:
Expert Commentary on the product profile of Belzutifan for Renal Cell CarcinomaIn an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
Latest:
Signaling Pathways in the Relapse of GlioblastomaJavier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Latest:
Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
